Related Experiment Video
Updated: Feb 16, 2026

Modeling Neural Immune Signaling of Episodic and Chronic Migraine Using Spreading Depression In Vitro
Published on: June 13, 2011
Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life
Cristina Tassorelli1,2, Gioacchino Tedeschi3, P Sarchielli4
1a Headache Science Center , National Neurological Institute C. Mondino , Pavia , Italy.
Introduction:
Management of chronic migraine is challenging. OnabotulinumtoxinA (OBT-A) is the only medication licensed for prevention of chronic migraine, and has been widely adopted in clinical practice. Limited data is available on its long-term use. Areas covered: Data from controlled trials are combined with available data on the long-term use of OBT-A in real-life studies, with information obtained in a recent survey among Italian headache centers, and the clinical experience of the authors. Six areas were identified as relevant to patients with chronic migraine: 1) definition of responders to OBT-A; 2) management of responders to OBT-A; 3) optimal timing of prophylaxis with OBT-A; 4) position of OBT-A in prevention of chronic migraine; 5) management of medication overuse, and 6) patient education. Expert commentary: This review provides an update on the latest evidence regarding the long-term use of OBT-A in chronic migraine and analyzes the critical issues in the decision-making process that emerge from the analysis of the literature and routine practice. A treatment algorithm is proposed for the adoption in the daily practice.
Insights
OnabotulinumtoxinA (OBT-A) is a key treatment for chronic migraine. This review synthesizes evidence on its long-term effectiveness and practical management strategies for optimal patient outcomes.
Area of Science:
- Neurology
- Pharmacology
Background:
- Chronic migraine management presents significant challenges.
- OnabotulinumtoxinA (OBT-A) is the sole licensed medication for chronic migraine prevention, widely used in clinical settings.
- Data on the long-term efficacy and application of OBT-A is limited.
Purpose of the Study:
- To provide an updated review of the latest evidence on the long-term use of OBT-A in chronic migraine.
- To analyze critical issues in OBT-A decision-making based on literature and clinical practice.
- To propose a treatment algorithm for daily clinical adoption.
Main Methods:
- Combination of data from controlled trials and real-world studies on OBT-A's long-term use.
- Inclusion of information from a survey of Italian headache centers.
- Incorporation of authors' clinical experience.
Main Results:
- Identified six key areas relevant to chronic migraine patients: defining responders, managing responders, optimal prophylaxis timing, OBT-A's role in prevention, medication overuse management, and patient education.
- Analysis of literature and routine practice highlights critical decision-making issues.
- A proposed treatment algorithm aims to guide daily clinical practice.
Conclusions:
- This review offers current evidence on long-term OBT-A use in chronic migraine.
- It addresses practical challenges and provides a framework for optimizing OBT-A therapy.
- The proposed algorithm supports informed clinical decision-making for chronic migraine management.
Related Concept Videos
Half-life of a Reaction
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Characteristics of Life
Chronic Obstructive Pulmonary Disease-V: Nursing Management
Assessment
Chronic Kidney Disease IV: Nursing Management
The Angiosperm Life Cycle

